Quantinno Capital Management LP Boosts Position in Catalyst Pharmaceuticals, Inc. $CPRX

Quantinno Capital Management LP increased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 180.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,885 shares of the biopharmaceutical company’s stock after acquiring an additional 21,794 shares during the quarter. Quantinno Capital Management LP’s holdings in Catalyst Pharmaceuticals were worth $839,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in CPRX. Smartleaf Asset Management LLC lifted its position in shares of Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 630 shares during the period. Clearstead Advisors LLC increased its position in shares of Catalyst Pharmaceuticals by 192.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 1,167 shares during the period. Larson Financial Group LLC lifted its holdings in Catalyst Pharmaceuticals by 552.7% in the fourth quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 1,564 shares during the period. Advisory Services Network LLC bought a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $39,000. Finally, Quarry LP purchased a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $40,000. 79.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on CPRX. Weiss Ratings upgraded Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Stephens set a $32.00 price target on Catalyst Pharmaceuticals in a research note on Thursday, May 7th. Zacks Research downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. HC Wainwright lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $35.00 to $31.50 in a research report on Thursday, May 28th. Finally, Oppenheimer cut shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $31.49 on Tuesday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The company has a 50 day simple moving average of $31.46 and a two-hundred day simple moving average of $28.26. The company has a market capitalization of $3.86 billion, a price-to-earnings ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).